Wegovy lists at $1,349/month. Zepbound at $1,059/month. Insurance coverage for GLP-1 weight loss medications is improving but remains inconsistent, confusing, and often requires significant patient advocacy. Here is the actual landscape and your realistic options.
The Coverage Reality in 2026
Coverage for GLP-1 medications varies dramatically depending on whether the indication is diabetes vs obesity:
- Diabetes indication (Ozempic, Mounjaro): Broadly covered by most commercial insurance plans with prior authorization. If you have type 2 diabetes, coverage is usually achievable.
- Obesity indication (Wegovy, Zepbound): Covered by approximately 40–50% of commercial employer plans as of 2026, up from 25% in 2023. Medicare Part D now covers Wegovy for cardiovascular risk reduction (post-SELECT trial) but still excludes pure weight loss indication for many plans. Medicaid coverage varies significantly by state.
Prior Authorization: What They Typically Require
Most insurance plans that cover GLP-1 weight loss medications require prior authorization with documentation of:
- BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
- Documentation of previous weight loss attempts (often 3–6 months of supervised dietary counseling or a structured weight loss program)
- Physician’s attestation of clinical necessity
- Sometimes: lab work showing metabolic comorbidities
The “previous weight loss attempt” requirement is the most common rejection reason. Keep records of any previous diet programs, gym memberships, or dietary counseling — even informal ones with your primary care physician documented in your chart.
Medicare Coverage — The SELECT Trial Changed Things
The SELECT trial (2023) demonstrated that semaglutide (Wegovy) reduced major cardiovascular events by 20% in patients with established cardiovascular disease and overweight/obesity — without diabetes. This created a new FDA indication for cardiovascular risk reduction.
As a result, Medicare Part D plans are required to cover Wegovy for patients with BMI ≥27 and established cardiovascular disease (prior heart attack, stroke, or peripheral arterial disease). This is a significant shift — Medicare previously excluded all weight loss medications. Check with your specific Part D plan for your cost-sharing details.
Manufacturer Savings Programs — Often Overlooked
Both Novo Nordisk and Eli Lilly run savings programs for commercially insured patients that can dramatically reduce out-of-pocket costs:
NovoCare (Wegovy/Ozempic)
- Eligible commercially insured patients: as low as $25/month for Wegovy
- Uninsured or coverage denied: Novo Nordisk Patient Assistance Program — free medication for qualifying patients below income thresholds
LillyDirect (Zepbound/Mounjaro)
- Eligible commercially insured patients: as low as $25/month for Zepbound
- Lilly Cares Foundation: assistance programs for uninsured/underinsured patients
Important: these savings programs do not apply to Medicare or Medicaid patients — federal law prohibits pharmaceutical companies from subsidizing federally-insured patient costs.
If Your Insurance Denies Coverage
A denial is not final. The appeals process works more often than patients expect:
- Request the specific denial reason in writing — insurers are required to provide this
- Have your physician submit a letter of medical necessity — specifically documenting your BMI, comorbidities, previous weight loss attempts, and why GLP-1 therapy is medically appropriate
- First-level appeal: Submit through your insurer’s standard appeals process with supporting documentation. Win rate approximately 30–40%.
- External review: If the first appeal is denied, request external independent review. Most states require insurers to comply with external reviewer decisions.
- Employer escalation: If you have employer-sponsored insurance, HR or benefits teams can sometimes escalate coverage disputes with the insurance carrier.
Without Coverage: The Self-Pay Path
For patients who cannot obtain insurance coverage and do not qualify for savings programs (particularly Medicare patients):
- Manufacturer-direct self-pay programs: NovoCare (Wegovy) and LillyDirect (Zepbound) offer the FDA-approved brand products without insurance at a fraction of list price — this is the cash-pay path YourMD uses. We do not prescribe compounded GLP-1s.
- Compounded semaglutide and tirzepatide are not a substitute: the FDA shortages ended in 2025, and compounded copies are generally no longer permitted except for a documented, patient-specific clinical need.
See our article on compounded semaglutide safety for the history of the shortage and why compounded copies are no longer an option.
HSA/FSA Use
GLP-1 medications prescribed for weight loss with a documented medical indication are generally eligible for HSA/FSA payment. This can provide a 22–37% effective discount depending on your tax bracket. Request an itemized receipt or superbill from your pharmacy for HSA/FSA reimbursement documentation.
References
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232.
- KFF. Coverage of Anti-Obesity Medications Under Medicare and Medicaid. 2024.
This article is for informational purposes only and does not constitute medical advice. Always consult with a licensed physician before starting any medication.
About the authorThis article was written and reviewed by
Dr. Teja V. Surapaneni, MD, MS — board-certified internal medicine physician with 10,000+ telehealth patients. All content reflects current clinical evidence.
Related Reading
Start Free Screening →Free async consult: a board-certified physician reviews your health screening — no appointment needed. If a phone or video visit is needed, your physician will contact you.
